| Heading: |
Batten Disease: Cerliponase Alfa |
| Question ID: |
1815316 |
| UIN: |
HL8693 |
| House: |
Lords |
| Date tabled: |
2025-06-23 |
| Asking Member ID: |
4884 |
| Asking Member display name: |
Lord Botham
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Lord Botham
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what discussions they have had with BioMarin and the National Institute for Health and Care Excellence regarding the long-term sustainability of access to Brineura for children with neuronal ceroid lipofuscinosis type 2 bey |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-01 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) is currently updating its guidance on the use of cerliponase alfa (Brineura) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) and has not yet published final guidance. NICE publ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |